Prostate cancer: ESMO Consensus Conference Guidelines 2012 (Q27022847)

S. Gillessen

18

0 references

Riccardo Valdagni

R. Valdagni

30

0 references

Gedske Daugaard

G. Daugaard

12

0 references

Theo M. de Reijke

3

T. de Reijke

1 reference

A. Horwich

1

1 reference

J. Hugosson

2

1 reference

T. Wiegel

4

1 reference

K. Fizazi

5

1 reference

C. Parker

7

1 reference

J. Bellmunt

8

1 reference

D. Berthold

9

1 reference

A. Bill-Axelson

10

1 reference

S. Carlsson

11

1 reference

G. De Meerleer

13

1 reference

D. Dearnaley

15

1 reference

V. Fonteyne

17

1 reference

D. Heinrich

19

1 reference

M. Kwiatkowski

23

1 reference

S. Nilsson

24

1 reference

A. Padhani

25

1 reference

C. Papandreou

26

1 reference

M. Roobol

28

1 reference

A. Sella

29

1 reference

T. Van der Kwast

31

1 reference

P. Verhagen

32

1 reference

language of work or name

1 reference

May 2013

1 reference

1 reference

24

1 reference

PubMed

issue

5

1 reference

PubMed

page(s)

1141-62

1 reference

Estimates of cancer incidence and mortality in Europe in 2008.

PubMed

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prostate specific antigen best practice statement: 2009 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

15-year followup of a population based prostate cancer screening study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Randomised prostate cancer screening trial: 20 year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prostate-cancer mortality at 11 years of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Population screening for prostate cancer: an overview of available studies and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) - Results from a prospective, population-based, randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Infectious complications and hospital admissions after prostate biopsy in a European randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The influence of family history on prostate cancer risk: implications for clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Family history and prostate cancer screening with prostate-specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Advances in magnetic resonance imaging: how they are changing the management of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

ESUR prostate MR guidelines 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

A graphical device to represent the outcomes of a logistic regression analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Active surveillance for prostate cancer: progress and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prostate cancer: radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Androgen deprivation therapy and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Intermittent androgen suppression for rising PSA level after radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Fetoscopic placement of a transurethral stent for intrauterine obstructive uropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Impact of surgical technique (open vs laparoscopic vs robotic-assisted) on pathological and biochemical outcomes following radical prostatectomy: an analysis using propensity score matching

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Comparative effectiveness of minimally invasive vs open radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Radical prostatectomy versus observation for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Current decision-making in prostate cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (CKTO 96-10 trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Radiotherapy after prostatectomy: is the evidence for dose escalation out there?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Salvage radiotherapy after prostatectomy - what is the best time to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Duration of androgen suppression in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a r

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Immunocytochemical localization of GnRH precursor in the hypothalamus of European starlings during sexual maturation and photorefractoriness

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The postchemotherapy PSA surge syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Prediction of Indolent Prostate Cancer: Validation and Updating of a Prognostic Nomogram

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS624

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS624

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

23303340

1 reference

Consolidated OpenCitations Corpus – April 2017